Melanotan II, a drug originally developed as a skin tanning agent, but subsequently investigated as a potential treatment for sexual dysfunction
•
Afamelanotide, originally developed under the names "Melanotan-1" or "Melanotan I" for skin tanning, a drug currently in trials in implant form as a prophylactic treatment for a series of light affected skin disorders and potential skin cancer preventative agent
A pilot Phase I clinical trial conducted on three males by the College of Medicine, Pharmacology Department, University of Arizona in Tucson, Arizona published in 1996 reported that, "Melanotan II has tanning activity in humans given only 5 low doses every other day by subcutaneous injection."